| Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer H Borghaei, L Paz-Ares, L Horn, DR Spigel, M Steins, NE Ready, ... New England Journal of Medicine 373 (17), 1627-1639, 2015 | 9572 | 2015 |
| Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer J Brahmer, KL Reckamp, P Baas, L Crinò, WEE Eberhardt, ... New England Journal of Medicine 373 (2), 123-135, 2015 | 8787 | 2015 |
| Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ... Annals of oncology 24 (9), 2206-2223, 2013 | 4301 | 2013 |
| Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer AT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, ... New England Journal of Medicine 368 (25), 2385-2394, 2013 | 4021 | 2013 |
| Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials Non-small Cell Lung Cancer Collaborative Group Bmj 311 (7010), 899-909, 1995 | 3398 | 1995 |
| 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer … JL Zamorano, P Lancellotti, D Rodriguez Munoz, V Aboyans, ... European heart journal 37 (36), 2768-2801, 2016 | 3186 | 2016 |
| First-line nivolumab in stage IV or recurrent non–small-cell lung cancer DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ... New England Journal of Medicine 376 (25), 2415-2426, 2017 | 2480 | 2017 |
| Drug-induced prolongation of the QT interval DM Roden New England Journal of Medicine 350 (10), 1013-1022, 2004 | 2346 | 2004 |
| Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ... Annals of oncology 26 (8), 1533-1546, 2015 | 2225 | 2015 |
| Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non–small-cell lung cancer F Cappuzzo, FR Hirsch, E Rossi, S Bartolini, GL Ceresoli, L Bemis, ... Journal of the National Cancer Institute 97 (9), 643-655, 2005 | 1960 | 2005 |
| Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy D Cardinale, A Colombo, G Bacchiani, I Tedeschi, CA Meroni, F Veglia, ... Circulation 131 (22), 1981-1988, 2015 | 1577 | 2015 |
| Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as … A Falcone, S Ricci, I Brunetti, E Pfanner, G Allegrini, C Barbara, L Crinò, ... Journal of clinical oncology 25 (13), 1670-1676, 2007 | 1493 | 2007 |
| De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ... Annals of Oncology 28 (8), 1700-1712, 2017 | 1237 | 2017 |
| 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4) F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ... Annals of Oncology 29 (8), 1634-1657, 2018 | 1224 | 2018 |
| Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer GV Scagliotti, F De Marinis, M Rinaldi, L Crino, C Gridelli, S Ricci, ... Journal of clinical oncology 20 (21), 4285-4291, 2002 | 1219 | 2002 |
| Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy … VA Miller, V Hirsh, J Cadranel, YM Chen, K Park, SW Kim, C Zhou, WC Su, ... The lancet oncology 13 (5), 528-538, 2012 | 1199 | 2012 |
| Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ... New England Journal of Medicine 382 (7), 597-609, 2020 | 1050 | 2020 |
| Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines G Curigliano, D Cardinale, T Suter, G Plataniotis, E de Azambuja, ... Annals of oncology 23, vii155-vii166, 2012 | 1043 | 2012 |
| 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, MS Aapro, F André, ... Annals of Oncology 31 (12), 1623-1649, 2020 | 1017 | 2020 |
| 3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3) F Cardoso, A Costa, E Senkus, M Aapro, F André, CH Barrios, J Bergh, ... The Breast 31, 244-259, 2017 | 873 | 2017 |
Giuseppe VialeUniversità di Milano e Istituto Europeo di OncologiaEmail verificata su ieo.it
